间充质干细胞治疗1型糖尿病的免疫调节机制研究进展  

Research Progress of Immune Modulation Mechanism of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus

作　　者：吴舟[1] 张双双[2] 陈宏[2] 

机构地区：[1]南方医科大学第二临床医学院,广州510282 [2]南方医科大学附属珠江医院内分泌与代谢病科,广州510282

出　　处：《医学综述》2012年第16期2555-2557,共3页Medical Recapitulate

基　　金：广东省自然科学基金(10151051501000095)

摘　　要：间充质干细胞(MSCs)是一类具有免疫调节功能的干细胞,近年来成为广为关注的有可能在抗移植排斥和自身免疫性疾病治疗中最有应用潜能的工具细胞。目前MSCs治疗1型糖尿病(T1DM)的机制依然不明了,途径主要有两个方向,一是直接在体外诱导MSCs分化为类胰岛细胞;二是通过利用MSCs的免疫调节途径,阻止T1DM自身免疫的发展。现仅针对MSCs治疗T1DM的免疫调节机制研究方面的进展进行综述。Mesenchymal stem cells（MSCs）have the capacity of mediating immune function.In recent years,it has become a most potential tool cell for novel therapeutic approaches aimed at inhibition of the immune responses.However,the mechanics of treatment of MSCs in type 1 diabetes mellitus（T1DM）is still unclear,there are two ways mainly,one possible channel is to be induced and differentiated in vitro into islet-like cells;the other is through the immune regulation properties of MSCs,aiming at suppressing the auto-immune reaction of T1DM.Here is to make a review on the immunomodulatory mechanisms of MSCs in the treatment of T1DM.

关 键 词：间充质干细胞 免疫调节 1型糖尿病 

分 类 号：R587[医药卫生—内分泌]